Saito T, Takahashi F, Katabuchi H (2017) 2016 committee on gynecologic oncology of the Japan Society of Obstetrics and Gynecology, annual report of the committee on gynecologic oncology, Japan Society of Obstetrics and Gynecology: patient annual report for 2014 and treatment annual report for 2009. J Obstet Gynaecol Res 43:1667–1677

Article  PubMed  Google Scholar 

Miller DS, Filiaci VL, Mannel RS et al (2020) Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol 38:3841–3850

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makker V, Colombo N, Herráez AC et al (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386:437–448

Article  CAS  PubMed  Google Scholar 

Yonemori K, Yunokawa M, Ushijima K et al (2022) Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: results from Study 309/KEYNOTE-775. Cancer Sci 113:3489–3497

Article  CAS  PubMed  PubMed Central  Google Scholar 

Booth CM, Tannock IF (2014) Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110:551–555

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dans AL, Dans LF, Guyatt GH et al (1998) Users’ guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 279:545–549

Article  CAS  PubMed  Google Scholar 

Meyer RM (2010) Generalizing the results of cancer clinical trials. J Clin Oncol 28:187–189

Article  PubMed  Google Scholar 

Khozin S, Blumenthal GM, Pazdur R (2017) Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst 109:djx187

Article  Google Scholar 

Booth CM, Karim S, Mackillop WJ (2019) Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol 16:312–325

Article  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Article  CAS  PubMed  Google Scholar 

Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105:109

Article  PubMed  Google Scholar 

Chiba Y, Kagabu M, Osakabe M et al (2024) A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Jpn J Clin Oncol 54:424–433

Article  PubMed  Google Scholar 

Kim J, Noh JJ, Lee TK et al (2022) Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: a multicenter study in Korea. Gynecol Oncol 165:369–375

Article  CAS  PubMed  Google Scholar 

How JA, Patel S, Fellman B et al (2021) Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 162:24–31

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zammarrelli WA 3rd, Ma W, Espino K et al (2023) Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. Gynecol Oncol 178:27–35

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tochigi M, Shigeta S, Shimada M et al (2024) Lenvatinib plus pembrolizumab combination therapy for advanced or recurrent endometrial cancer: a single-center, retrospective analysis. Tohoku J Exp Med 262:85–95

Article  CAS  PubMed  Google Scholar 

Sasaki R, Fukushima M, Haraguchi M et al (2019) Response to lenvatinib is associated with optimal relative dose intensity in hepatocellular carcinoma: experience in clinical settings. Cancers (Basel) 11:1769

Article  CAS  PubMed  Google Scholar 

Kirino S, Tsuchiya K, Kurosaki M et al (2020) Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE 15:e0231828

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi A, Moriguchi M, Seko Y et al (2019) Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma. Anticancer Res 39:5149–5156

Article  CAS  PubMed  Google Scholar 

Fukuda N, Toda K, Wang X et al (2021) Prognostic significance of 8 weeks’ relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Endocr J 68:639–647

Article  CAS  PubMed  Google Scholar 

Yonemori K, Fujiwara K, Hasegawa K et al (2024) Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. J Gynecol Oncol 35:e40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makker V et al. ASCO2022 Abst#5587